Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate and interferon alfa may interfere with the growth of the cancer
cells. Combining imatinib mesylate with interferon alfa may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining imatinib mesylate with
interferon alfa in treating patients who have chronic myelogenous leukemia.